GSK plc
No SEC Form 4 filings for $GSK in the last 30 days.
See all $GSK insider activity →European stocks ended mixed as Middle East conflict and uncertainty around the Strait of Hormuz weighed on sentiment, while easing concerns about Fed rates followed tame US inflation. Stoxx 600 fell 0.21%, with CAC 40 down 0.16% and DAX up 0.53%. UK’s Sage Group rose 4.5%. Valneva jumped 20% after EMA validated its Lyme vaccine application.
Europe stocks were mixed. London’s FTSE 100 fell 0.2% to 10,750.11, while the FTSE 250 rose 0.1% to 24,867.42. Weak mining and pharma weighed; Entain rose 2.1% and Aviva gained 1.8% after results. Antofagasta dropped 4.6% and GSK and AstraZeneca fell 2.1%. US retail sales fell 0.6% in July, shifting rate expectations.
Britain’s FTSE 100 fell for a fifth straight session, closing down 22.56 points (0.21%) at 10,750.11. Mining stocks led the decline after Antofagasta cut its copper outlook, while AstraZeneca and GSK fell more than 2% each. FTSE 250 rose 0.1%. The week saw FTSE 100 down 1.4%.
Over the past 7 days, alphai's AI scored 14 news stories mentioning GSK (GSK plc). Coverage has skewed bullish: 6 bullish, 3 neutral, and 5 bearish.
Recent GSK coverage spans market movers, regulation and earnings.
The move is framed as part of a pharma selloff, useful for sector-relative positioning.
Pharma weakness appears sector-driven in this wrap, with no company-specific new catalyst provided for GSK.
Pharma sector selling is pressuring GSK, but without a disclosed company-specific driver.
AZN and GSK appear to be trading on sector risk rather than company-specific catalysts.
Pipeline acceleration and cost-savings are supportive, but the discontinued camlipixant program and impairment highlight execution and portfolio risk.
alphai scores every news story that mentions GSK with an AI model for sentiment and relevance, and aggregates insider trades from GSK plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
European stocks ended mixed as Middle East conflict and uncertainty around the Strait of Hormuz weighed on sentiment, while easing concerns about Fed rates followed tame US inflation. Stoxx 600 fell 0.21%, with CAC 40 down 0.16% and DAX up 0.53%. UK’s Sage Group rose 4.5%. Valneva jumped 20% after EMA validated its Lyme vaccine application.
7 min readEurope stocks were mixed. London’s FTSE 100 fell 0.2% to 10,750.11, while the FTSE 250 rose 0.1% to 24,867.42. Weak mining and pharma weighed; Entain rose 2.1% and Aviva gained 1.8% after results. Antofagasta dropped 4.6% and GSK and AstraZeneca fell 2.1%. US retail sales fell 0.6% in July, shifting rate expectations.
7 min readBritain’s FTSE 100 fell for a fifth straight session, closing down 22.56 points (0.21%) at 10,750.11. Mining stocks led the decline after Antofagasta cut its copper outlook, while AstraZeneca and GSK fell more than 2% each. FTSE 250 rose 0.1%. The week saw FTSE 100 down 1.4%.
6 min readThe FTSE 100 ended the week lower, extending losses for a fifth straight session. Mining stocks fell on weaker industrial metal prices, including Antofagasta (-4%+), Glencore (-2%), and Anglo American and Rio Tinto (-1%+). Pharma stocks also declined, with AstraZeneca and GSK down 2%+. Shell rose 1%. Aviva gained nearly 2% after reporting a 24% first-half profit increase. The week fell about 1.4%.
2 min readGSK plc reported Q2 results on July 28. Total turnover was £8.4bn, up 5% CER. Core operating profit rose 7% CER to £2.80bn and Core EPS increased 9% CER to 50.5p, driven by Specialty Medicines and Vaccines. Total operating profit fell 75% CER due to a £1.3bn non-cash impairment after discontinuing camlipixant. GSK also outlined a 2026 Phase III acceleration plan and a £1.9bn annual cost-savings restructuring program.
7 min readGlaxoSmithKline Pharmaceuticals Ltd. (GSK India) launched a postal ballot to seek shareholder approval for re-appointing Managing Director Bhushan Akshikar for a two-year term from Dec 1, 2026, and appointing Karine J F Natland as a Non-Executive Director. E-voting runs Aug 14 to Sep 13, 2026, results by Sep 15. In Q1FY27, standalone PAT rose 24% to ₹253.33 crore and revenue rose 15% to ₹924.42 crore; consolidated revenue rose 16.5% to ₹9,384.4 crore.
6 min readBiopharma M&A in 2026 is estimated at $130B across 42 deals, nearly matching 2025’s $133B, according to IQVIA. Average deal size rose to $3.1B. The article cites patent expirations as a driver and highlights deals including GSK-Nuvalent ($10.6B), Merck-Terns ($6.7B), AbbVie-Apogee ($10.9B), Curium-Lantheus (up to $8B), Eli Lilly-Centessa ($7.8B), and Sun Pharma-Organon ($11.75B).
6 min readReuters reports President Trump’s order to administer separate measles, mumps and rubella shots faces regulatory and manufacturing hurdles in the US. Merck and GSK say there is no evidence supporting separation; Merck says FDA approval and manufacturing could take up to 10 years. Combined MMR is licensed, while single shots are not. Merck (MRK) and GSK are central.
6 min readThe FTSE 100 was little changed on Tuesday, lagging other European markets. Defensive stocks fell, including AstraZeneca (-1%), GSK (-1.5%) and Unilever (-0.6%), while energy rose, with Shell (+1.4%) and BP (+1.8%). Oil gains eased after renewed Middle East agreement hopes. InterContinental Hotels Group fell over 2%, and Bellway warned on outlook. UK retail sales rose 1.3% y/y, and Barclays cited consumer spending up 2% y/y.
2 min readOn 5 Aug, Delhi High Court Justice Jyoti Singh granted GSK an ex-parte ad-interim injunction restraining Scott Edil Pharmacia and affiliate from selling or advertising “Nexporin” and “Zetum”. The court found the marks deceptively similar to GSK’s registered “Neosporin” and “Ceftum” and ordered removal of related listings within two weeks.
4 min read
